PFX · Class II · 21 CFR 866.5920

FDA Product Code PFX: System, Microarray-based, Genome-wide, Postnatal Chromosomal Abnormality Detection

A Microarray-based, Genome-wide, Postnatal Chromosomal Abnormality Detection System Is Used To Qualitatively Detect Constitutional Gains And Losses In Chromosomal Copy Numbers Across The Human Genome Using Microarray Methods. It Is Intended As An Aid In The Postnatal Diagnosis Of Developmental Delay And/or Intellectual Disability (dd/id), Congenital Anomalies, And Dysmorphic Features In Conjunction With Other Clinical Information Currently Used In Postnatal Diagnosis. It Is Not Intended To Be Used For Standalone Diagnostic Purposes, Prenatal Or Pre-implantation Testing Or Screening, Population Screening, Or For The Detection Of, Or Screening For, Acquired Or Somatic Genetic Aberrations.

2
Total
1
Cleared
142d
Avg days
2014
Since

FDA 510(k) Cleared System, Microarray-based, Genome-wide, Postnatal Chromosomal Abnormality Detection Devices (Product Code PFX)

2 devices
1–2 of 2
No devices found for this product code.

About Product Code PFX - Regulatory Context